F. Mitchell

发表

Imaging Pharmacodynamics of the alpha Folate Targeted Thymidylate Synthase Inhibitor BGC 945

E. Aboagye, A. Jackman, M. Forster, 2014 .

Targeted Thymidylate Synthase Inhibitor BGC 945 −-Folate Receptor α Imaging Pharmacodynamics of the Updated

E. Aboagye, A. Jackman, M. Forster, 2008 .

Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.

E. Aboagye, A. Jackman, M. Forster, 2008, Cancer research.

A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies

M. Gore, R. Ruddle, W. Aherne, 2005, British Journal of Cancer.

Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.

P. Beale, I. Judson, E. Douglass, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.

M. Valenti, F. Raynaud, A. Jackman, 2005, Cancer research.

A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.

M. Highley, R. Plummer, P. Beale, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a 5-day continuous infusion every 3 weeks

P. Beale, I. Judson, A. Jackman, 1999 .

Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.

I. Judson, D. Cunningham, A. Jackman, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Modified high-performance liquid chromatography assay for the measurement of 2'-deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs.

A. Jackman, F. Mitchell, S. Lynn, 2000, Journal of chromatography. B, Biomedical sciences and applications.

Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to A-Folate Receptor – Overexpressing Tumors

M. Valenti, F. Raynaud, A. Jackman, 2005 .

The design and synthesis of water-soluble analogues of CB30865, a quinazolin-4-one-based antitumor agent.

A. Jackman, V. Bavetsias, B. Allan, 2002, Journal of medicinal chemistry.

Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.

C. L. van der Wilt, D. Priest, G. Jansen, 2001, Cancer research.

The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.

M. Walton, G. Aherne, A. Jackman, 1998, British Journal of Cancer.

Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography.

H. Barthel, E. Aboagye, A. Jackman, 2006, Cancer research.

Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.

E. Aboagye, A. Jackman, M. Forster, 2008, Cancer research.